On 20 June 2024, PTC Therapeutics reported initial 12-month data from the PIVOT-HD trial, showing dose-dependent mHTT lowering in the blood and cerebrospinal fluid, and early evidence for potential clinical benefits. For more information, click here. […]
Kategorie: Uncategorized
Clinical trial update: Sage Therapeutics reported topline data on the Phase 2 SURVEYOR study
On 11 June 2024, Sage Therapeutics reported topline data on the Phase 2 SURVEYOR study confirming that the primary endpoint was met and no new safety concerns emerged. Read the full press release. […]
Video Postcard – 19th Annual HD Therapeutics Conference from Palm Springs
The Postcard from Palm Springs video from the 19th Annual HD Therapeutics Conference held February 26 – 29, 2024, in Palm Springs, California, is now available to view online. […]
EHDN PODCAST | Juvenile and Paediatric HD
Episode #1: Introduction: What is Juvenile and Pediatric HD? […]
10th Congress of the European Academy of Neurology – Helsinki 2024 – June 29-July 2
[…]
Gratitude Day 2024
March 23, 1993 is the date when the mutation that causes Huntington’s disease was first published. We launched Gratitude Day as a way of honoring the families who made this discovery possible. […]
EHDN Newsletter – 51st edition
The EHDN newsletter (archive) aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July 1, Nov 1). To receive EHDN news going forward, please subscribe to the EHDN news at the […]
29 February is Rare Disease Day
[…]
Call for Nominations 2024
We are seeking nominations for the EHDN Executive Committee (EC). If you are interested in being part of the EC, or would like to nominate somebody, […]
Roche-EHDN Virtual Meeting – 12Feb2024
On February 12, 2024, the EHDN has hosted a virtual platform meeting on the Generation-HD1 trial to discuss the previously published data. The video of this meeting is available. […]